What is PCVX's current stock price?

PCVX (Vaxcyte, Inc.) is currently trading at $47.30 with a market cap of $6.83B.

What sector is Vaxcyte, Inc. in?

Vaxcyte, Inc. (PCVX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PCVX a good stock to buy?

Analysts have a Buy consensus on PCVX with a price target of $89.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PCVX Vaxcyte, Inc.

Healthcare

$47.30-0.19%ClosedMarket Cap: $6.83B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.20

P/S

0.00

EV/EBITDA

-7.07

DCF Value

$-0.57

FCF Yield

-11.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-32.5%

ROA

-28.3%

ROIC

-35.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-320.6M	$—
Q4 null	$0.00	$-246.5M	$—
FY null	$0.00	$-766.6M	$—
Q3 null	$0.00	$-212.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$89.00

Target (Median)

$89.00

Target Range

$89.00 - $89.00

1 Strong Buy9 Buy1 Hold0 Sell0 Strong Sell

BTIGBuy

2026-02-26

GuggenheimBuy

2026-02-02

BTIGBuy

2025-11-10

Trading Activity

Insider Trades

View All

Wassil Jimofficer: CHIEF OPERATING OFFICER

SellFri May 01

Cowan Elviaofficer: SVP, Finance & CAO

SellWed Apr 08

Cowan Elviaofficer: SVP, Finance & CAO

SellWed Apr 08

Wassil Jimofficer: CHIEF OPERATING OFFICER

SellFri Apr 03

Wassil Jimofficer: CHIEF OPERATING OFFICER

SellFri Apr 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.30

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Peers